Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale

European Neuropsychopharmacology

Volumn 25, Issue 2, 2015, Pages 176-184

  Keefe, Richard S E ^a,b   Davis, Vicki G ^b   Spagnola, Nathan B ^b   Hilt, Dana ^c   Dgetluck, Nancy ^c   Ruse, Stacy ^b   Patterson, Thomas D ^d   Narasimhan, Meera ^e   Harvey, Philip D ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NeuroCog Trials Inc   (United States)

^c FORUM Pharmaceuticals   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Assessment; Cognition; Cognitive impairment; Schizophrenia; SCoRS; Treatment response

Indexed keywords

ENCENICLINE; PLACEBO; BUNGAROTOXIN RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CAUCASIAN; COGNITION ASSESSMENT; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; EFFECT SIZE; FACTORIAL ANALYSIS; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOM ERROR; SCHIZOPHRENIA; SCHIZOPHRENIA COGNITION RATING SCALE; SCORING SYSTEM; SYSTEMATIC ERROR; TEST RETEST RELIABILITY; TREATMENT RESPONSE; VALIDITY; WORKING MEMORY; AGONISTS; CLINICAL TRIAL; COGNITION; COGNITION DISORDERS; DRUG EFFECTS; EUROPE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGIC TEST; PSYCHOLOGY; PSYCHOMETRY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UNITED STATES; VALIDATION STUDY;

ADULT; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; EUROPE; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84930793669     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.06.009     Document Type: Article

References (20)

1. Barch D.M., Carter C.S., Arnsten A., Buchanan R.W., Cohen J.D., Geyer M., Green M.F., Krystal J.H., Nuechterlein K., Robbins T., Silverstein S., Smith E.E., Strauss M., Wykes T., Heinssen R. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr. Bull. 2009, 35:109-114.
2. Bellack A.S., Green M.F., Cook J.A., Fenton W., Harvey P.D., Heaton R.K., Laughren T., Leon A.C., Mayo D.J., Patrick D.L., Patterson T.L., Rose A., Stover E., Wykes T. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr. Bull. 2007, 33:805-822.
3. Bowie C.R., Twamley E.W., Anderson H., Halpern B., Patterson T.L., Harvey P.D. Self-assessment of functional status in schizophrenia. J. Psychiatr. Res. 2006, 41:1012-1018.
4. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S.E., Leon A., Nuechterlein K., Laughren T., Levin R., Stover E., Fenton W., Marder S. A summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31:5-19.
5. Buchanan R.W., Keefe R.S.E., Umbricht D., Green M.F., Laughren T., Marder S.R. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?. Schizophr. Bull. 2011, 37:1209-1217.
6. Burton C.Z., Vella L., Harvey P.D., Patterson T.L., Heaton R.K., Twamley E.W. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. Schizophr. Res. 2013, 146:244-248.
7. Chapman L.J., Chapman J.P. Problems in the measurement of cognitive deficit. Psychol. Bull. 1973, 79:380-385.
8. Dickinson D., Ragland J.D., Calkins M.E., Gold J.M., Gur R.C. A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr. Res. 2006, 85:20-29.
9. Green M.F., Nuechterlein K.H., Kern R.S., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S.E., Mesholam-Gately R., Seidman L.J., Stover E., Marder S.R. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. Am. J. Psychiatry. 2008, 165:221-228.
10. Green M.F., Schooler N.R., Kern R.S., Frese F.J., Granberry W., Harvey P.D., Karson C.N., Peters N., Stewart M., Seidman L.J., Sonnenberg J., Stone W.S., Walling D., Stover E., Marder S.R. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am. J. Psychiatry. 2011, 168:400-407.
11. Harvey P.D., Ogasa M., Cucchiaro J., Loebel A., Keefe R.S. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 2011, 127:188-194.
12. Hilt, D.C., 2011. EVP-6124, an Alpha-7 Nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. In: Proceedings of the Poster presentation at the 50th Annual ACNP Meeting, Hollywood, FL, December 4-8.
13. Keefe, R.S.E., 2014. Sharpening the signal in cognitive enhancement trials. In: Proceedings of the Symposia presented at the 4th Annual SIRS Meeting,Florence, Italy, April 5-9.
14. Keefe R.S.E., Poe M., Walker T.M., Kang J.W., Harvey P.D. The Schizophrenia Cognition Rating Scale (SCoRS): interview-based assessment and its relationship to cognition, real-world functioning and functional capacity. Am. J. Psychiatry. 2006, 163:426-432.
15. Noh J., Kim J.H., Hong K.S., Kim N., Nam H.J., Lee D., Yoon S.C. Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patients. J. Korean Med. Sci. 2010, 25:276-282.
16. Nuechterlein K.H., Green M.F. MATRICS Consensus Cognitive Battery Manual 2006, MATRICS Assessment, Inc., Los Angeles, Ca.
17. Patterson T.L., Semple S.J., Shaw W.S., Grant I., Jeste D.V. Researching the caregiver: family members who care for older psychotic patients. Psychiatr. Ann. 1996, 26:772-784.
18. Sabbag S., Twamley E.M., Vella L., Heaton R.K., Patterson T.L., Harvey P.D. Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr. Res. 2011, 131:250-255.
19. Spreen O., Strauss E. A Compendium of Neuropsychological Tests 1998, Oxford University Press, New York. second edition.
20. Ventura J., Reise S.P., Keefe R.S., Hurford I.M., Wood R.C., Bilder R.M. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr. Bull. 2013, 39:583-591.